Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming pat

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess dem

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zac

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and c

Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 mi

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.31 per share which missed t

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company deve

Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is p

Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, a

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company deve

COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expec

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that managem

Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional

– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pedi

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and c

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company deve

Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO r

Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 m

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.24 per share which met the

 Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TV

Citizens analyst Jason N. Butler maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Market O

Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 m

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.01) per share which missed t

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-We

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were update

Ironwood Pharmaceuticals (IRWD) stock rose with high volume on Friday, releasing financial guidance

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-We

Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2025 sales outlook from $260.000 million-$290.000 mi

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.24 per share which beat the

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-1st-drug-children-7-years-and-older-i